Major progress in ex vivo T cell-depleted haploidentical HSCT at AMCCH. In 2008, allogenetic HSCT from haploidentical family donor was initiated at our center using CD3-depleted grafts after reduced-intensity conditioning (RIC) with cacineurin inhibitors (CI) and mycophenolate mofetil (MMF) for the prevention of graft versus host disease (GVHD). Our early experience with CD3-depleted haploidentical HSCT showed a high incidence of graft failure (GF); therefore, low-dose total body irradiation (LD-TBI) was added to the conditioning regimen in an attempt to decrease GF in early 2011. In addition, the infused cell dose was targeted after add-back of T cells from negative selection product. The targeted dose of CD3⁺ T cells was gradually reduced from 1-5×10⁶/kg to 6-8×10⁵/kg to decrease the risk of severe GVHD and ensure stable engraftment. At the end of 2012, the ex vivo αβ⁺ T cell depletion technique with targeted dose of αβ cells at 1-5×10⁵/kg by add-back was introduced. The depletion efficacy improved with the use of anti-TCRαβ monoclonal antibody instead of anti-CD3 monoclonal antibody for depletion, leading to ≤5×10⁴/kg of recipient body weight of the residual αβ⁺ T cells. At the end of 2015, immunosuppressive drugs to prevent GVHD were eliminated for αβ-depleted haploidentical HSCT.